G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/577 (2006.01) C07K 16/18 (2006.01) G01N 33/566 (2006.01) G01N 33/68 (2006.01) G01N 33/74 (2006.01)
Patent
CA 2152676
The present invention provides an assay that distinguishes those patients with imminent delivery with intact membranes from those in whom the membranes have ruptured. The method comprises obtaining a cervicovaginal secretion sample from a pregnant patient determined to be as at risk for imminent delivery by detection of a biochemical marker for imminent delivery in a cervicovaginal secretion sample from the patient and determining the level of IGFBP-1 in the sample. If the level of IGFBP-1 is elevated, the patient has rupture of membranes. If IGFBP-1 is not present, the patient has intact membranes. In a preferred embodiment, the method comprises obtaining a cericovaginal secretion sample from a pregnant patient after about week 20 of gestation and determining the level of fetal fibronectin and IGFBP-1 in the sample. The presence of an elevated fibronectin level in the sample indicates an increased risk of imminent delivery. If the level of IGFBP-l is elevated, the patient had rupture of membranes. If IGFBP-1 is not present, the patient has intact membranes. If IGFBP-I is not present, the IGFBP-I assay is preferably repeated. In those patients with an increased level of IGFBP-I, the test indicates that delivery cannot be delayed.
Casal David C.
Leavitt John C.
Varma Madhu
Adeza Biomedical Corporation
Smart & Biggar
LandOfFree
Assay method to rule out rupture of membranes in women at... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay method to rule out rupture of membranes in women at..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay method to rule out rupture of membranes in women at... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1617372